Alkem Labs gets 7 USFDA observations at Daman Plant after 12-day audit
Synopsis
Alkem Laboratories' Daman plant has drawn USFDA attention with seven Form 483 observations after a 12-day inspection — even as the same facility earned a European GMP compliance certificate just months ago. The dual regulatory signals highlight the divergent standards and scrutiny timelines that Indian pharma exporters must navigate simultaneously.
Key Takeaways
Alkem Laboratories received a Form 483 with seven observations from the USFDA following an audit of its Amaliya, Daman facility.
The inspection ran for 12 days , from 20 April to 1 May 2026 .
Alkem has committed to responding to all seven observations within the stipulated timeline but has not disclosed the specific issues flagged.
The development was disclosed to BSE Limited and the National Stock Exchange of India (NSE) on 2 May 2026 .
In contrast, the same Daman facility received a European Union GMP compliance certificate from the Malta Medicines Authority in March 2026 , valid for three years.
Separately, drug maker Lupin also received a Form 483 with three observations after a USFDA inspection conducted between 13 and 17 April 2026 .
Alkem Laboratories, one of India's leading pharmaceutical companies, has come under regulatory scrutiny after the United States Food and Drug Administration (USFDA) issued seven inspectional observations at its manufacturing facility in Amaliya, Daman, following a 12-day audit. The inspection, conducted from 20 April to 1 May 2026, concluded with the issuance of a Form 483, a formal notice flagging conditions that may potentially violate provisions of the Food, Drug and Cosmetic Act.
What the USFDA Inspection Found
The Form 483 — formally termed a
Point of View
Which relies heavily on US generic drug approvals for revenue, a seven-observation Form 483 is not a warning shot to be dismissed. The industry's broader pattern of recurring USFDA observations — Lupin received its own Form 483 just weeks earlier — suggests systemic quality governance gaps that individual responses to regulators cannot fully resolve. Investors and analysts will watch whether Alkem's response leads to a Warning Letter or a clean resolution, as the outcome will signal the depth of the compliance issues at the Daman plant.
NationPress
5 Jul 2026
Frequently Asked Questions
What is a USFDA Form 483 and why does it matter for Alkem Laboratories?
A Form 483, formally called a 'Notice of Inspectional Observations,' is issued by the USFDA when investigators identify conditions at a facility that may violate the Food, Drug and Cosmetic Act. For Alkem Laboratories, receiving seven such observations at its Daman plant signals potential manufacturing or quality system deficiencies that must be addressed within a stipulated timeline to avoid further regulatory action such as a Warning Letter.
How long did the USFDA inspection of Alkem's Daman plant last?
The USFDA inspection of Alkem Laboratories' manufacturing facility in Amaliya, Daman lasted 12 days, running from 20 April to 1 May 2026. It concluded with the issuance of a Form 483 carrying seven observations.
Did Alkem disclose the specific issues flagged by the USFDA?
No. Alkem Laboratories acknowledged receiving the seven observations but did not publicly disclose the specific issues raised by the regulator. The company said it would respond to all observations within the stipulated timeline.
How does the USFDA action square with Alkem's recent European GMP certification?
In March 2026, the same Daman facility received a Good Manufacturing Practice (GMP) compliance certificate from the Malta Medicines Authority, confirming it met European Union GMP standards. The certificate, valid for three years, followed a December 2025 inspection. The USFDA and EU regulators audit against different standards, so a facility can hold EU GMP certification and still receive USFDA observations simultaneously.
Has any other Indian pharma company faced similar USFDA scrutiny recently?
Yes. Drug maker Lupin received a Form 483 with three observations following a USFDA inspection conducted between 13 and 17 April 2026, just weeks before Alkem's disclosure. The back-to-back incidents reflect ongoing USFDA scrutiny of Indian pharmaceutical manufacturing facilities.
